Eric Bleickardt

7.5k citations
40 papers · 4.2k · 2 hit papers · h-index 20

Impact in

  • Hematology top 0.1%
    • Chronic Myeloid Leukemia Treatments
    • Multiple Myeloma Research and Treatments
    • Acute Myeloid Leukemia Research
  • Genetics top 0.2%
    • Chronic Lymphocytic Leukemia Research

Papers in

    • Chronic Myeloid Leukemia Treatments 22
    • Multiple Myeloma Research and Treatments 12
    • Chronic Lymphocytic Leukemia Research 20

Eric Bleickardt

39 papers receiving 4.0k citations

Eric Bleickardt's Hit Papers

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia 2010 · 1.2k citations
1.2k0+6+13Years since publication4008001.2k

Peers

Eric Bleickardt
Comparison fields: 5 of 79
  • Hematology 3.3k
  • Genetics 2.0k
  • Rheumatology 1.3k
  • Oncology 859
  • Public Health, Environmental and Occupational Health 335
Replace Charles Chuah with:
Charles Chuah Singapore
Shu Tamura Japan
Michael J. Mauro United States
Zbigniew Rudzki Australia
Stephen G. O’Brien United Kingdom
Elisabetta Abruzzese Italy
Christopher A. Eide United States
Jaspal Kaeda United Kingdom
Hans D. Menssen United States
Philipp Erben Germany
Eric Bleickardt relative to Charles Chuah Singapore Charles Chuah's profile →
Citations per field
00.5×1.5×
Charles Chuah · 1×
Citations per year

Countries citing papers authored by Eric Bleickardt

Since Specialization
Citations

This map shows the geographic impact of Eric Bleickardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Bleickardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Bleickardt more than expected).

Fields of papers citing papers by Eric Bleickardt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Bleickardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Bleickardt. The network helps show where Eric Bleickardt may publish in the future.

Co-authors

The 25 scholars most cited alongside Eric Bleickardt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eric Bleickardt Line = papers co-authored together Eric Bleickardt links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
Hit paper breakdown →
20061346
2
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hit paper breakdown →
20101160
3 2008386
4 2016187
5 2008184
6 2009180
7 2015132
8 201563
9 201962
10 200950
11 201640
12 200840
13 200930
14 201428
15 200826
16 200725
17 200522
18 200721
19 200221
20 200520

About Eric Bleickardt

Eric Bleickardt is a scholar working on Hematology, Genetics, Oncology, Rheumatology and Molecular Biology, having authored 40 papers that have together received 4.2k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (22 papers), Chronic Lymphocytic Leukemia Research (20 papers), Multiple Myeloma Research and Treatments (12 papers), Eosinophilic Disorders and Syndromes (12 papers), Protein Degradation and Inhibitors (4 papers), Cancer therapeutics and mechanisms (4 papers), CAR-T cell therapy research (4 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Hematology (3.3k citations), Genetics (2.0k citations), Rheumatology (1.3k citations), Oncology (859 citations) and Public Health, Environmental and Occupational Health (335 citations). Eric Bleickardt has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Hagop M. Kantarjian, Neil P. Shah, Jörge E. Cortes, Charles L. Sawyers, Claude Nicaise, John Nicoll, Andreas Hochhaus, Tai‐Tsang Chen, Moshe Talpaz and Nicholas J. Donato. Their work appears in journals such as Blood, Journal of Clinical Oncology, New England Journal of Medicine, Cancer and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact